Johnson & Johnson Family of Companies
NEWS
Denmark-based Genmab A/S released topline data from its Phase III MAIA trial of a drug it licensed to Johnson & Johnson’s Janssen Biotech, Darzalex (daratumumab).
Johnson & Johnson’s JLABS incubator in San Francisco recently convened a meeting of biopharma industry executives. One of the hot topics for one of the panels was the competition for talent.
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
As more and more lawsuits are filed by state and local governments over the opioid epidemic, drugmakers are fighting back in court by demanding the allegations include specifics on how the companies are to blame.
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
In August, Pfizer filed with the U.S. Food and Drug Administration (FDA) accusing Amgen and Roche of using social media to mislead doctors and patients about biosimilars and their effectiveness.
Although race is thought of as a social concept, ‘there’s growing evidence that, whether for environmental or genetic reasons, drugs may have different effects on different populations.’
Opioid manufacturers have been the target of thousands of lawsuits from state and local governments seeking to reclaim funds that have been spent on addressing treatment for opioid abuse and overdoses.
Arrowhead announced a deal with Johnson & Johnson that could conceivably be worth over $3.7 billion, with J&J agreeing to pick up a minor stake in the company, including the task of cultivating and promoting its ARO-HBV Hepatitis B drug.
JOBS
IN THE PRESS